Abstract: Immunofusion molecules useful for 5T4-targeted therapy. The immunofusion molecules include the 5T4 anti-gen-binding portion of an anti-5T4 antibody engineered into a single chain form and fused to a cytotoxic payload, such as, human pancreatic RNase (“HPRN”). The RNase portion of the single immunofusion peptide may be fused to a polyglutamic acid (polyE) tail. A pharmaceutical composition includes an immunofusion molecule including a 5T4 antigen-binding portion and HPRN and methods of administering the composition to an animal in need.

Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.

Abstract: The present invention provides methods of treating cancer cells comprising administering to a patient in need thereof a therapeutically effective amount of a non-specific antibody conjugated to a cytotoxin, wherein the cancer cells do not express an antigen to which the non-specific antibody binds. In one embodiment, the non-specific antibody is an anti-CD33 antibody (e.g., hp67.6), an anti-CD22 antibody (e.g., g5/44), or an anti-CD20 antibody (e.g., rituximab). In another embodiment, the non-specific antibody does not bind a human antigen. The cancer cells treated can be, e.g., gastric, colon, non-small cell lung (NSCLC), breast, epidermoid, or prostate carcinoma cells. In one embodiment, the cytotoxin is calicheamicin. Calicheamicin can be conjugated to the non-specific antibody using a 4-(4?-acetylphenoxy)butanoic acid (AcBut) or (3-Acetylphenyl)acetic acid (AcPAc) linker.

Abstract: The present invention provides methods for the treatment and/or prevention of thrombocytopenia including thrombocytopenia associated with drug-induced liver damage and thrombocytopenia associated with drug-induced bone marrow destruction. The methods of treatment of the invention include administration of interleukin-11 to a subject suffering from or susceptible to thrombocytopenia and/or receiving or about to receive a treatment involving a conjugate therapeutic agent whose administration results in thrombocytopenia. Also provided are pharmaceutical compositions and kits useful for carrying out such methods of treatment.

Abstract: Methods for determining pharmacokinetics of targeted therapies.

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.

Abstract: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.

Abstract: Anti-Lewis Y antibodies are described. Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Specifically, monomeric calicheamicin derivative/anti-Lewis Y antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.

Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

Abstract: Soluble fusion molecules were prepared which contained a CD11a/CD18 specific binding region operatively linked to an immunoglobulin constant region. These molecules particularly include extracellular portions of adhesion molecules such as ICAM-1 and ICAM-2 attached to IgG constant regions.The fusion molecules described are utilized as costimulatory agents for the activation of T cells and in methods for increasing CD4.sup.+ T cell proliferative response and IL-2 induction.